There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Media formats available:
Details
Presenters
Related
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Daniel Gaudet, MD, PhD
Professor of Medicine
University de Montreal
Montreal, CanadaDr. Gaudet has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Contracted Research/Consulting Fees: Alnylam, Amgen, Applied Therapeutics, Arrowhead, Boehringer Ingelhein, Chiesi (Amryt), CRISPR Therapeutics, Eli Lilly, Esperion, Ionis, Kowa, New Amsterdam Pharma, Novartis, NovoNordisk, Pfizer, Regeneron, Sanofi, Ultragenyx, Uniqure, Verve Therapeutics
Børge G. Nordestgaard, MD
Chief Physician in Clinical Biochemistry
Copenhagen University Hospital
Professor in Genetic Epidemiology
University of Copenhagen
Copenhagen, DenmarkDr. Nordestgaard has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisor/Consultant: Abbott, Akcea, Amarin, Amgen, AstraZeneca, Denka, Esperion, Kowa, Lilly, Mankind, Novartis, Novo Nordisk, Regeneron, Sanofi, Silence Therapeutics, Ultragenyx, and USV.
Kausik Ray, MD
President, European Atherosclerosis Society
Director, Imperial Centre for
Cardiovascular Disease Prevention
Imperial College London
London, UKDr. Ray has no relevant relationships to disclose.
Pam Taub, MD, FACC
Founder and Director of Step Family
Cardiac Rehabilitation and Wellness Center
Dir. of Preventive Cardiology, Prof. of Medicine
UC San Diego Health System
San Diego, CADr. Taub has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisor/Consultant: Amgen, Bayer, Boehringer Ingelheim, Edwards, Esperion, Jazz, Lilly, Medtronic, Novartis, Novo Nordisk, Sanofi
Contracted Researcher: Dysautonomia International, Hillblom Network, NIH R01 DK118278Reviewers/Content Planners/Authors:
- Tim Person has no relevant relationships to disclose.
- Anja Gerrits has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Evaluate the clinical characteristics and diagnostic criteria of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), including their impact on patient outcomes and quality of life
- Assess the relationship between triglyceride levels and risk of acute pancreatitis and ASCVD
- Compare and contrast the mechanisms of action of siRNA- and ASO-targeting therapies in APOC3 inhibition
- Interpret the efficacy and safety profiles of novel APOC3 inhibitors based on recent clinical trial data in patients with FCS, SHTG, and mixed hyperlipidemia
Target Audience
This activity has been designed to meet the educational needs of cardiologists (lipidologists) and endocrinologists as well as all other physicians and healthcare providers involved in managing patients with FCS and SHTG.
Accreditation and Credit Designation Statements
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 60 minutes of effective education time.Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.Commercial Support
This activity is supported by an independent educational grant from Arrowhead Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medcon International. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medcon International you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
